RAD1901 is an investigational drug.
There have been 6 clinical trials for RAD1901.
The most recent clinical trial was a Phase 2 trial, which was initiated on May 10th 2019.
The most common disease conditions in clinical trials are Breast Neoplasms, Hot Flashes, and [disabled in preview]. The leading clinical trial sponsors are Radius Pharmaceuticals, Inc., Radius Health, Inc., and Context Therapeutics Inc.
There are fourteen US patents protecting this investigational drug and one hundred and forty-seven international patents.